MedTrace Logo

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

NCT00901498 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2011-01-07

No results posted yet for this study

Summary

The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.

Conditions

Interventions

DRUG

BMS-708163

Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.

DRUG

BMS-708163

Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings

DRUG

BMS-708163

Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings

DRUG

BMS-708163

Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings

DRUG

BMS-708163

Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901498 on ClinicalTrials.gov